美国感染病学会2023年抗菌药物耐药革兰阴性菌感染治疗指南
美国感染病学会(IDSA)发布2023年指南,针对产超广谱β-内酰胺酶肠杆菌目、产AmpC酶肠杆菌目、碳青霉烯耐药肠杆菌目、难治性耐药铜绿假单胞菌、碳青霉烯耐药鲍曼不动杆菌和嗜麦芽窄食单胞菌感染提供首选和替代治疗方案。指南假设病原体已明确且药敏结果已知,适用于美国成人和儿童,但剂量仅提供成人数据。建议耐药感染治疗咨询感染病专科医生。
要点
- 指南涵盖ESBL-E、AmpC-E、CRE、DTR-P. aeruginosa、CRAB和S. maltophilia六类耐药革兰阴性菌感染。
- 提供首选和替代治疗方案及理由,假设病原体已鉴定且药敏结果已知。
- 建议耐药感染治疗咨询感染病专科医生,指南截至2022年12月31日。
核心结论
- 抗菌药物耐药领域高度动态,建议耐药感染治疗咨询感染病专科医生。
研究设计与样本
- 由六名具有耐药感染管理专长的感染病专家组成小组制定问题并形成建议。
主要发现
- 针对ESBL-E、AmpC-E、CRE、DTR-P. aeruginosa、CRAB和S. maltophilia感染提供首选和替代治疗方案及理由。
关键数值与推荐
- 建议的治疗方案适用于成人和儿童,但建议的抗生素剂量仅提供成人数据。
临床怎么用
- 对于耐药革兰阴性菌感染,可参考本指南选择首选或替代治疗方案。
- 建议耐药感染治疗咨询感染病专科医生。
- 经验性治疗、转为口服治疗、疗程及其他管理考虑也有简要讨论。
局限性
- 由于国际上耐药流行病学和特定抗感染药物可及性存在差异,本文件聚焦于美国感染的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. METHODS: A panel of six infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by ESBL-E, AmpC-E, CRE, DTR-P. aeruginosa, CRAB, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. RESULTS: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. CONCLUSIONS: The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of December 31, 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
引用
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023. PMID: 37463564. doi:10.1093/cid/ciad428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。